CVS Caremark manages prescription drug benefits for approximately 25 million to 30 million Americans on its standard commercial formulary, and its decisions about weight loss medications like Mounjaro and Zepbound directly affect what patients pay and which treatment they can access.
Mounjaro is FDA-approved for Type 2 diabetes only, while Zepbound carries the FDA weight management approval, though both contain identical tirzepatide from Eli Lilly. CVS Caremark removed Zepbound from its formulary July 1, 2025, shifted preferred status to Wegovy, then reversed course in May 2026, with Zepbound set to return October 1, 2026.
This guide covers why Mounjaro does not qualify for weight loss coverage, how to pursue a formulary exception through the prior authorization process, and what cash-pay and self-pay options exist for members who need tirzepatide now.
Does CVS Caremark Cover Mounjaro for Weight Loss?
CVS Caremark does not cover Mounjaro for weight loss because the FDA approved Mounjaro exclusively for Type 2 diabetes management, not for obesity or chronic weight management, and insurance coverage follows FDA-approved indications rather than a drug’s active ingredient or off-label clinical uses. CVS Caremark covers Zepbound, which contains the same active ingredient, tirzepatide, as the approved weight loss option under its formularies.
Mounjaro and Zepbound both contain tirzepatide at identical doses and strengths. The FDA approved Mounjaro for Type 2 diabetes in 2022. The FDA approved Zepbound for chronic weight management in 2023. Insurance plans treat the two brand names as entirely separate drugs for coverage purposes.
CVS Caremark formulary rules assign Mounjaro to the diabetes drug pathway. A member seeking tirzepatide for weight loss must pursue Zepbound coverage, not Mounjaro. Both brand names share the same manufacturer, Eli Lilly, but follow different insurance tracks entirely.
Is Mounjaro FDA-Approved for Weight Loss?
No. Mounjaro is FDA-approved only as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with Type 2 diabetes, and the FDA has not approved Mounjaro for weight loss, obesity, or chronic weight management under any patient population or prescribing circumstance. Weight management approvals fall under the Zepbound brand name only.
Eli Lilly received FDA approval for Zepbound in November 2023 for chronic weight management. Zepbound targets adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Mounjaro carries no weight management indication from the FDA.
Off-label prescribing of Mounjaro for weight loss does not change insurance coverage rules. CVS Caremark applies coverage based on FDA-approved indications. An off-label Mounjaro prescription for weight loss will not qualify for standard weight loss drug benefits.
What Is the Difference Between Mounjaro and Zepbound?
Mounjaro and Zepbound are two brand names for tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and manufactured at identical doses and strengths, but the FDA-approved indication assigned to each brand determines how CVS Caremark classifies and covers them on its commercial formularies. The chemistry is the same. The insurance pathway is not.
Mounjaro targets the diabetes drug market. Zepbound targets the weight management market. Both work through the same tirzepatide mechanism, but the formulary route each drug follows through CVS Caremark differs entirely based on the FDA label attached to the brand name.
A patient with Type 2 diabetes currently taking Mounjaro faces no coverage disruption under CVS Caremark. A patient using tirzepatide for weight loss must use the Zepbound brand and follow the weight management coverage pathway. The brand name on the prescription matters.
Mounjaro vs. Zepbound: Key Differences:
| Feature | Mounjaro | Zepbound |
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA Approval | Type 2 Diabetes (2022) | Chronic Weight Management (2023) |
| CVS Caremark Coverage | Diabetes pathway only | Weight loss pathway |
| Manufacturer | Eli Lilly | Eli Lilly |
| Monthly List Price | Comparable to Zepbound | $1,086 |
How Does CVS Caremark Determine Drug Coverage?
CVS Caremark is the largest pharmacy benefit manager in the United States, managing prescription benefits for approximately 25 million to 30 million members on its standard commercial formulary, and it uses clinical criteria, quarterly formulary reviews, and manufacturer rebate negotiations to determine which drugs are covered and at what cost tier for plan members. Plan sponsors, typically employers, retain final authority over which drugs their specific plan covers.
CVS Caremark reviews its formulary each quarter. A drug can shift between coverage tiers, be removed entirely, or return to the formulary based on rebate negotiations and clinical evidence reviews. Each quarterly change can affect millions of members at once.
Formulary decisions determine copay levels, prior authorization requirements, and step therapy rules. A tier 2 drug costs less out of pocket than a tier 3 drug. A drug removed from the formulary requires a formulary exception request before coverage applies.
What Is a Pharmacy Formulary?
A pharmacy formulary is a tiered list of prescription drugs covered under a pharmacy benefit plan, updated quarterly by CVS Caremark, that determines the out-of-pocket cost a member pays at the pharmacy counter and whether a medication requires prior authorization before the plan will cover it. Drugs absent from the formulary require a formal exception request for coverage to apply.
Tier 1 drugs carry the lowest copays. Tier 2 drugs carry moderate copays. Tier 3 drugs carry the highest copays within the covered tier structure. A drug without a formulary slot requires either exception approval or full cash payment from the member.
A formulary removal does not eliminate an entire drug class from coverage. CVS Caremark’s removal of Zepbound in 2025 still left Wegovy, Saxenda, Qsymia, and Orlistat available as covered weight loss alternatives on its standard commercial formularies.
Why Do PBMs Control Which Drugs Are Covered?
Pharmacy benefit managers like CVS Caremark control drug coverage decisions by using formulary placement as a negotiation tool to secure rebates and pricing discounts from pharmaceutical manufacturers, a practice documented by the Commonwealth Fund as the primary driver of formulary decisions that affect access for millions of patients across the country. Higher rebates from one manufacturer can shift preferred status away from a competing drug, regardless of clinical outcomes.
PBMs act as intermediaries between insurance plans, drug manufacturers, and pharmacies. They negotiate prices, process claims, and set formulary terms that determine what members pay and which drugs receive preferred status. CVS Caremark’s 2026 formulary strategy projected $4.46 billion in client savings from its approach.
Employers who adopt CVS Caremark template formularies can customize coverage at the plan level. A standard formulary change applies across all plans using that template. Individual employers retain the right to maintain coverage for drugs removed from the standard template by paying additional plan costs.
Does CVS Caremark Cover Zepbound Instead of Mounjaro?
CVS Caremark covers Zepbound as the preferred tirzepatide-based weight loss option, with Zepbound scheduled to return to CVS Caremark commercial formularies as an additional preferred medication on October 1, 2026, after being removed from the standard formulary on July 1, 2025, when Wegovy became the preferred GLP-1 weight loss drug. Mounjaro remains covered for diabetes members only, with no weight loss coverage pathway through any CVS Caremark formulary.
The July 2025 formulary change sparked immediate patient backlash. Patients reported better outcomes on Zepbound than on Wegovy and pushed back hard against mandatory switches. A class-action lawsuit challenging the formulary decision was filed in September 2025 and remains active.
CVS Caremark announced in May 2026 that Zepbound would return to commercial formularies October 1, 2026. Some members with private insurance could access Zepbound at a $25 copay following the reinstatement, depending on the employer plan design.
When Did CVS Caremark Change Its Zepbound Formulary?
CVS Caremark removed Zepbound from its standard commercial formulary effective July 1, 2025, automatically transferring existing Zepbound prior authorizations to Wegovy and contacting prescribers on behalf of members to request Wegovy prescriptions, a change that affected approximately 25 million to 30 million members on the standard formulary. The reversal was announced May 2026, with Zepbound returning October 1, 2026.
Patients who had achieved significant weight loss on Zepbound faced forced switches to Wegovy despite documented better personal outcomes on tirzepatide specifically. The patient backlash and subsequent class-action lawsuit appear to have accelerated the formulary reversal timeline.
Foundayo, an oral GLP-1 pill approved by the FDA in April 2026, also joined CVS Caremark formularies starting June 1, 2026. The two additions together expanded GLP-1 weight management options significantly heading into late 2026.
What Weight Loss Drugs Does CVS Caremark Cover Now?
CVS Caremark currently lists Wegovy (semaglutide) as the preferred GLP-1 weight loss medication on its standard commercial formulary, alongside Saxenda, Qsymia, and Orlistat as additional covered weight management alternatives, with Zepbound set to return as a preferred option on October 1, 2026, and Foundayo added effective June 1, 2026. Not every employer plan covers all of these options.
Weight loss medications moved off the high-deductible health plan preventive drug list. Members on high-deductible plans now pay full drug costs until their annual deductible is met. This applies to every weight management drug on the current CVS Caremark formulary, not just Zepbound.
Members who switched to Wegovy after the July 2025 formulary change continue coverage through their existing prescription. Members wanting to switch back to Zepbound after October 2026 should consult their prescriber about updated prior authorization requirements at that time.
Currently Covered CVS Caremark Weight Loss Medications:
- Wegovy (semaglutide) — preferred GLP-1 injectable
- Zepbound (tirzepatide) — returning October 1, 2026
- Foundayo (orforglipron) — oral GLP-1, added June 1, 2026
- Saxenda (liraglutide) — injectable GLP-1 alternative
- Qsymia (phentermine/topiramate) — oral combination
- Orlistat — lipase inhibitor, lower cost option
How Can You Get Tirzepatide Covered Through CVS Caremark?
A member seeking tirzepatide coverage through CVS Caremark must follow a three-step pathway starting with a prior authorization request for Zepbound, followed by a formulary exception with a Letter of Medical Necessity if that initial request is denied, then a formal appeal if the exception is also denied, with prescriber involvement required at every stage of the process. Most initial requests require at least one denial before the formal exception review proceeds.
CVS Caremark reviews all exception and appeal requests against established clinical criteria. The provider must submit supporting documentation including chart notes, laboratory results, and a detailed medical necessity explanation. Members cannot initiate the formal exception process without a provider submission on their behalf.
Members who previously tried Wegovy and experienced intolerable side effects or insufficient weight loss have a documented clinical basis for the exception request. Exception requests could be submitted as early as June 16, 2025 to minimize any coverage gap during the July 2025 formulary transition.
What Is a Prior Authorization for Weight Loss Medications?
A prior authorization is an advance approval requirement from CVS Caremark that the prescribing provider must obtain before a weight loss medication is covered under the member’s plan, based on a clinical documentation review confirming the member meets established coverage criteria and formulary requirements for the requested drug. CVS Caremark automatically transferred existing Zepbound prior authorizations to Wegovy in July 2025 without requiring members to initiate new applications.
A new prior authorization for Zepbound after the July 2025 formulary removal was likely to receive an initial denial. That denial is not the end of the process. The written denial generates the documentation trail needed for the formal formulary exception step that follows.
Providers should request the denial letter in writing and retain the case reference number from every submission. Written denial notices include appeal instructions and filing deadlines. Missing these deadlines eliminates the formal appeal pathway entirely.
How Do You Request a Formulary Exception for Zepbound?
A formulary exception for Zepbound requires the prescribing provider to submit a Letter of Medical Necessity to CVS Caremark explaining in clinical terms why tirzepatide is medically necessary over the currently preferred alternative, with providers able to call 855-240-0536 to initiate the exception request directly and submit required supporting clinical documentation for review. Both the member and prescriber receive the exception decision in writing upon completion.
Strong exception applications include documented adverse reactions to Wegovy such as severe gastrointestinal effects, evidence of co-existing conditions such as obstructive sleep apnea, and clinical records showing 5% or more body weight loss specifically on tirzepatide. Each data point strengthens the medical necessity case.
If an exception is approved, the applicable copay tier determines the member’s cost. CVS Caremark assigns tier 2 copay to Mounjaro exceptions. Tier 3 copay applies to Zepbound exceptions. Both tiers are considerably less costly than full cash-pay pricing at list rates.
Steps to Request a Formulary Exception Through CVS Caremark:
- Ask the prescribing provider to submit a new prior authorization for Zepbound (initial denial is expected and required to proceed)
- Receive the written denial with case reference number
- Provider submits a Letter of Medical Necessity to CVS Caremark explaining clinical need for tirzepatide over Wegovy
- Provider calls 855-240-0536 or submits documentation through the CVS Caremark provider portal
- CVS Caremark reviews the exception request and notifies both member and provider of the decision
- If approved, member fills Zepbound at the applicable copay tier
What Happens If CVS Caremark Denies Your Coverage Request?
A coverage denial from CVS Caremark includes written instructions specifying the deadline for filing a formal appeal and the exact documentation required for the review, giving members a clear next step to challenge the denial without losing access to the appeals process, with both the member and prescriber notified of the denial and appeal details simultaneously. The denial is not a final answer if the member files a timely appeal with complete documentation.
Here is what that actually means: a denial letter is the beginning of the appeals process, not the end. Additional clinical documentation from the prescriber strengthens the appeal at each stage. Updated chart notes, new laboratory results, and specialist evaluations all count as supporting evidence in the appeal review.
CVS Caremark reviews appeals on a case-by-case basis. The review considers clinical history, prior treatment response, and the medical necessity argument made by the provider. Both the member and the prescriber receive the appeal outcome in writing after the review period closes.
What Documentation Is Needed to Appeal a Denial?
A CVS Caremark appeal for tirzepatide weight loss coverage requires the prescriber to submit a Letter of Medical Necessity, documented clinical evidence of adverse reactions to the formulary-preferred alternative such as Wegovy, and chart notes showing the member’s complete treatment history and clinical response to prior weight management medications. The denial notice specifies the exact submission requirements and filing deadline for each individual case.
Documented adverse reactions to Wegovy carry significant weight in the CVS Caremark review. Severe nausea, vomiting, or gastrointestinal side effects recorded in the patient chart establish medical necessity for a clinically different option. The prescriber should include the onset, severity, and duration of each adverse reaction in the documentation.
Co-existing conditions strengthen the appeal by expanding the clinical picture beyond weight alone. Evidence of 5% or more body weight loss specifically on tirzepatide documents the member’s individual response to the requested drug versus the formulary alternatives.
Supporting Documentation Checklist for CVS Caremark Appeal:
- Letter of Medical Necessity from the prescribing provider
- Documented adverse reactions to Wegovy or other preferred alternatives
- Chart notes showing BMI history and comorbidities
- Evidence of prior treatment response (5%+ weight loss on tirzepatide)
- Documentation of co-existing conditions (obstructive sleep apnea, hypertension, dyslipidemia)
- Laboratory results supporting the clinical necessity argument
- Denial letter with case reference number and appeal deadline
How Long Does the CVS Caremark Exception Review Take?
CVS Caremark processes standard formulary exception requests within 72 hours per federal guidelines once complete documentation is received, with expedited reviews available when a delay would seriously jeopardize the member’s health, and both the member and prescriber notified of the decision in writing upon completion of the review. Prescribers must document the clinical urgency in the submission to qualify for expedited processing.
Standard reviews allow 72 hours from the time CVS Caremark receives complete documentation from the provider. Expedited reviews apply when standard timelines would cause serious patient harm. Prescribers initiate expedited processing by explicitly documenting clinical urgency in the exception request.
Members who submitted exception requests before the July 1, 2025 formulary change could initiate the process starting June 16, 2025 to minimize coverage gaps. Members filing after the change date follow standard review timelines and cannot access the pre-transition exception window retroactively.
How Much Does Tirzepatide Cost Without CVS Caremark Coverage?
Zepbound carries a monthly list price of $1,086, and Mounjaro carries a comparable list price as a branded tirzepatide product from Eli Lilly, though cash-pay discounts available through the LillyDirect program can reduce out-of-pocket costs below list price while still leaving most patients paying several hundred dollars per month. Neither branded version is affordable at full list price without manufacturer savings assistance or insurance coverage.
LillyDirect is Eli Lilly’s direct-to-patient program providing access to both Mounjaro and Zepbound at manufacturer-reduced pricing. Patients without insurance coverage or with denied coverage claims can access tirzepatide through LillyDirect. Patients should contact LillyDirect directly for current pricing, as savings program rates change without public notice.
High-deductible health plan members pay the full drug cost until their annual deductible is met, even for formulary-covered medications. Once the deductible clears, standard copay rates apply for all remaining fills that plan year. Annual total spending requires adding early-year full-cost payments to post-deductible copay amounts.
Ready to start losing weight faster while navigating the coverage process? A structured nutrition and diet plan keeps results moving regardless of where the insurance timeline stands.
Does Lilly Offer Discounts for Cash-Pay Patients?
Eli Lilly offers savings programs through LillyDirect for patients paying cash for tirzepatide, reducing costs from the Zepbound list price of $1,086 per month, and patients with qualifying private insurance may access Zepbound at as low as a $25 copay when Zepbound returns to CVS Caremark standard formularies on October 1, 2026. Cash-pay discounts reduce list price but do not eliminate the significant monthly cost burden for most patients.
The $25 copay tier applies only to members whose employer plans adopt the updated CVS Caremark standard formulary naming Zepbound as an additional preferred option. Employers retain the right to customize their plan terms. Some members will pay higher amounts depending on how their specific employer plan adopts the formulary update.
Patients using LillyDirect bypass the insurance system entirely. The program connects patients directly with manufacturer savings on tirzepatide prescriptions for both Mounjaro and Zepbound. Current discount amounts require verification directly through LillyDirect, as program pricing changes without advance notice.
What Self-Pay Options Exist for Weight Loss Medications?
Patients without tirzepatide coverage through CVS Caremark can access self-pay options including LillyDirect for FDA-approved Zepbound and Mounjaro, manufacturer savings programs from Novo Nordisk for Wegovy, and compounding pharmacies that produce tirzepatide at lower price points but without FDA oversight of the finished compounded drug product. Each option carries different cost levels, access requirements, and regulatory standing.
LillyDirect provides manufacturer-direct pricing for FDA-approved tirzepatide. Compounding pharmacy versions contain tirzepatide as the active ingredient but are not FDA-approved finished drug products. The FDA has raised specific safety concerns about compounded tirzepatide and recommends patients use only the FDA-approved branded versions when available.
Self-Pay Options for Tirzepatide and Weight Loss Drugs:
- LillyDirect — manufacturer savings on Mounjaro and Zepbound directly from Eli Lilly
- Novo Nordisk savings programs — discount access to Wegovy for cash-pay patients
- GoodRx and pharmacy discount cards — reduce retail pricing at participating pharmacies
- Compounding pharmacies — lower cost tirzepatide not subject to FDA finished-product oversight
- High-deductible plan strategy — front-load spending to clear deductible early in the plan year
Who Qualifies for CVS Caremark Weight Loss Drug Coverage?
A member qualifies for CVS Caremark GLP-1 weight loss drug coverage when the employer plan sponsor elects to include weight management medications in the plan’s benefit design and the member meets clinical criteria including a BMI of 30 or higher, or a BMI of 27 or higher with a documented weight-related comorbidity such as Type 2 diabetes, hypertension, or obstructive sleep apnea. Not all CVS Caremark employer plans include GLP-1 weight management coverage at all.
CVS Caremark plan sponsors, typically employers, make the primary coverage decision about whether to include weight loss drugs. Adding GLP-1 coverage significantly increases plan drug costs. Many employers opt out of GLP-1 weight loss coverage entirely to manage overall drug spend. A member’s coverage eligibility starts with confirming whether the specific employer plan covers weight management drugs at all.
Members whose plans cover weight loss drugs must still meet clinical criteria and obtain prior authorization approval. A BMI of 30 or higher meets the obesity threshold on its own. A BMI of 27 or higher with a qualifying comorbidity meets the overweight-plus-comorbidity threshold. Prescribers should document BMI and each relevant comorbidity in the prior authorization request.
What Medical Criteria Does CVS Caremark Require for GLP-1s?
CVS Caremark requires members to meet clinical obesity criteria, defined as a BMI of 30 or higher or a BMI of 27 or higher with at least one documented weight-related comorbidity, and to receive prior authorization approval before any GLP-1 weight loss medication becomes covered under the member’s benefit plan. Step therapy requirements may also apply, meaning a member must try a lower-cost medication before GLP-1 approval is granted.
Qualifying comorbidities for the BMI 27 threshold include obstructive sleep apnea, hypertension, dyslipidemia, and Type 2 diabetes. Prescribers should document each comorbidity specifically in the prior authorization. Missing comorbidity documentation is the most common preventable reason for prior authorization denials on GLP-1 requests.
Members who previously tried a formulary-preferred alternative and failed may qualify for a formulary exception. Clinical records showing less than 5% body weight loss on the preferred drug, or documented intolerable side effects, support the exception case for moving to a different GLP-1 option.
BMI Eligibility Thresholds for CVS Caremark GLP-1 Coverage:
| BMI Range | Qualifying Condition | Coverage Pathway |
| 30 or above | Obesity (no comorbidity required) | Standard prior authorization |
| 27 to 29.9 | Overweight plus Type 2 diabetes | Prior authorization with comorbidity documentation |
| 27 to 29.9 | Overweight plus hypertension | Prior authorization with comorbidity documentation |
| 27 to 29.9 | Overweight plus obstructive sleep apnea | Prior authorization with comorbidity documentation |
| 27 to 29.9 | Overweight plus dyslipidemia | Prior authorization with comorbidity documentation |
Ready for Your Free Weight Loss Medication Guide From Eat Proteins?
Navigating CVS Caremark coverage for tirzepatide takes time, documentation, and multiple steps. But the process is manageable when you know exactly what to do at each stage.
Our nutritionists at Eat Proteins put together a free guide covering GLP-1 medications, what to eat while waiting for prior authorization approval, and how to keep weight loss moving during any coverage gap. You have the science. Now get the plan. Don’t wait on a coverage decision to start making progress.
Sign up below and our team at Eat Proteins will send the full guide straight to your inbox. It is free. And it works alongside any medication journey, approved or pending.